Sung Hoon Kang1,2,3, Jeonghun Kim4, Jun Pyo Kim1,2, Soo Hyun Cho5, Yeong Sim Choe1,2,6, Hyemin Jang1,2, Hee Jin Kim1,2, Seong-Beom Koh3, Duk L Na1,2, Joon-Kyung Seong7,8,9, Sang Won Seo10,11,12,13,14. 1. Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, 06351, Seoul, South Korea. 2. Neuroscience Center, Samsung Medical Center, Seoul, 06351, South Korea. 3. Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, South Korea. 4. Medical & Health Device Division, Korea Testing Laboratory, Seoul, South Korea. 5. Department of Neurology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, South Korea. 6. Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, South Korea. 7. Department of Artificial Intelligence, Korea University, Seoul, South Korea. jkseong@korea.ac.kr. 8. School of Biomedical Engineering, Korea University, Seoul, South Korea. jkseong@korea.ac.kr. 9. Interdisciplinary Program in Precision Public Health, Korea University, Seoul, South Korea. jkseong@korea.ac.kr. 10. Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, 06351, Seoul, South Korea. sw72.seo@samsung.com. 11. Neuroscience Center, Samsung Medical Center, Seoul, 06351, South Korea. sw72.seo@samsung.com. 12. Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, South Korea. sw72.seo@samsung.com. 13. Department of Intelligent Precision Healthcare Convergence, SAIHST, Sungkyunkwan University, Seoul, South Korea. sw72.seo@samsung.com. 14. Samsung Alzheimer Research Center, Center for Clinical Epidemiology Medical Center, Seoul, South Korea. sw72.seo@samsung.com.
Abstract
PURPOSE: In this study, we used machine learning to develop a new method derived from a ligand-independent amyloid (Aβ) positron emission tomography (PET) classifier to harmonise different Aβ ligands. METHODS: We obtained 107 paired 18F-florbetaben (FBB) and 18F-flutemetamol (FMM) PET images at the Samsung Medical Centre. To apply the method to FMM ligand, we transferred the previously developed FBB PET classifier to test similar features from the FMM PET images for application to FMM, which in turn developed a ligand-independent Aβ PET classifier. We explored the concordance rates of our classifier in detecting cortical and striatal Aβ positivity. We investigated the correlation of machine learning-based cortical tracer uptake (ML-CTU) values quantified by the classifier between FBB and FMM. RESULTS: This classifier achieved high classification accuracy (area under the curve = 0.958) even with different Aβ PET ligands. In addition, the concordance rate of FBB and FMM using the classifier (87.5%) was good to excellent, which seemed to be higher than that in visual assessment (82.7%) and lower than that in standardised uptake value ratio cut-off categorisation (93.3%). FBB and FMM ML-CTU values were highly correlated with each other (R = 0.903). CONCLUSION: Our findings suggested that our novel classifier may harmonise FBB and FMM ligands in the clinical setting which in turn facilitate the biomarker-guided diagnosis and trials of anti-Aβ treatment in the research field.
PURPOSE: In this study, we used machine learning to develop a new method derived from a ligand-independent amyloid (Aβ) positron emission tomography (PET) classifier to harmonise different Aβ ligands. METHODS: We obtained 107 paired 18F-florbetaben (FBB) and 18F-flutemetamol (FMM) PET images at the Samsung Medical Centre. To apply the method to FMM ligand, we transferred the previously developed FBB PET classifier to test similar features from the FMM PET images for application to FMM, which in turn developed a ligand-independent Aβ PET classifier. We explored the concordance rates of our classifier in detecting cortical and striatal Aβ positivity. We investigated the correlation of machine learning-based cortical tracer uptake (ML-CTU) values quantified by the classifier between FBB and FMM. RESULTS: This classifier achieved high classification accuracy (area under the curve = 0.958) even with different Aβ PET ligands. In addition, the concordance rate of FBB and FMM using the classifier (87.5%) was good to excellent, which seemed to be higher than that in visual assessment (82.7%) and lower than that in standardised uptake value ratio cut-off categorisation (93.3%). FBB and FMM ML-CTU values were highly correlated with each other (R = 0.903). CONCLUSION: Our findings suggested that our novel classifier may harmonise FBB and FMM ligands in the clinical setting which in turn facilitate the biomarker-guided diagnosis and trials of anti-Aβ treatment in the research field.
Authors: Juha O Rinne; Dean F Wong; David A Wolk; Ville Leinonen; Steven E Arnold; Chris Buckley; Adrian Smith; Richard McLain; Paul F Sherwin; Gill Farrar; Marita Kailajärvi; Igor D Grachev Journal: Acta Neuropathol Date: 2012-10-10 Impact factor: 17.088
Authors: Soo Hyun Cho; Jeong-Hyeon Shin; Hyemin Jang; Seongbeom Park; Hee Jin Kim; Si Eun Kim; Seung Joo Kim; Yeshin Kim; Jin San Lee; Duk L Na; Samuel N Lockhart; Gil D Rabinovici; Joon-Kyung Seong; Sang Won Seo Journal: Eur J Nucl Med Mol Imaging Date: 2018-07-06 Impact factor: 9.236
Authors: Soo Hyun Cho; Yeong Sim Choe; Young Ju Kim; Hee Jin Kim; Hyemin Jang; Yeshin Kim; Si Eun Kim; Seung Joo Kim; Jun Pyo Kim; Young Hee Jung; Byeong C Kim; Samuel N Lockhart; Gill Farrar; Duk L Na; Seung Hwan Moon; Sang Won Seo Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: William E Klunk; Henry Engler; Agneta Nordberg; Yanming Wang; Gunnar Blomqvist; Daniel P Holt; Mats Bergström; Irina Savitcheva; Guo-feng Huang; Sergio Estrada; Birgitta Ausén; Manik L Debnath; Julien Barletta; Julie C Price; Johan Sandell; Brian J Lopresti; Anders Wall; Pernilla Koivisto; Gunnar Antoni; Chester A Mathis; Bengt Långström Journal: Ann Neurol Date: 2004-03 Impact factor: 10.422
Authors: Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling Journal: Alzheimers Dement Date: 2018-04 Impact factor: 21.566
Authors: Bernard J Hanseeuw; Rebecca A Betensky; Elizabeth C Mormino; Aaron P Schultz; Jorge Sepulcre; John A Becker; Heidi I L Jacobs; Rachel F Buckley; Molly R LaPoint; Patrizia Vannini; Nancy J Donovan; Jasmeer P Chhatwal; Gad A Marshall; Kathryn V Papp; Rebecca E Amariglio; Dorene M Rentz; Reisa A Sperling; Keith A Johnson Journal: Alzheimers Dement Date: 2018-05-21 Impact factor: 21.566
Authors: Milos D Ikonomovic; Chris J Buckley; Kerstin Heurling; Paul Sherwin; Paul A Jones; Michelle Zanette; Chester A Mathis; William E Klunk; Aruna Chakrabarty; James Ironside; Azzam Ismail; Colin Smith; Dietmar R Thal; Thomas G Beach; Gill Farrar; Adrian P L Smith Journal: Acta Neuropathol Commun Date: 2016-12-12 Impact factor: 7.801